Alexandria Real Estate stock builds on lab space demand
Published on 07/10/2026 at 14:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Alexandria Real Estate Equities, Inc. (ISIN US0152711022) is a large-cap U.S. life science real estate investment trust focused on laboratory and research campuses for biotechnology and pharmaceutical tenants.
Business model
The company owns and develops properties designed for scientific research, which makes its cash flow tied to long lease structures and tenant demand in research hubs such as Boston, San Diego, and the San Francisco Bay Area. That portfolio mix gives Alexandria a structural link to U.S. health-care innovation spending.
Market context
For investors, the key issue is the balance between durable lab-space demand and the capital costs that come with developing specialized real estate. In life science property, peers and sector conditions often matter as much as single-quarter operating numbers.
Representative property focus
Alexandria's platform centers on campus-style laboratory buildings and related amenities that are built for research-intensive users rather than traditional office tenants. That specialization is the company's core differentiator.
Stock context
Alexandria Real Estate Equities trades on the New York Stock Exchange under the ticker ARE. As of July 10, 2026, 12:39 p.m. ET, the shares are priced at $0.00 USD.
Fact box
- Company: Alexandria Real Estate Equities, Inc.
- ISIN: US0152711022
- Ticker: ARE
- Exchange: New York Stock Exchange
- Price (as of July 10, 2026, 12:39 p.m. ET): $0.00 USD
- Sector / Industry: Real Estate / Office REITs
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
